TAIPEI, Taiwan I March 26, 2025 I AnHorn Medicines, a pioneering AI-driven new drug discovery company, is pleased to announce that, AH-001, a first-in-class ...

EMERYVILLE, CA, USA I March 26, 2025 I Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO) with a next ...

Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further ...

Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world – ...

Bayer obtains exclusive worldwide license for MTA-cooperative PRMT5 inhibitor for selective targeting of MTAP-deleted tumors ...

PARIS, France I March 26, 2025 I The US Food and Drug Administration has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention ...

CHENGDU, China I March 25, 2025 I Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical ...

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All ...

PLANO, TX & BALTIMORE, MD, USA I March 25, 2025 I Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from ...

GUANGDONG, China and BAGSVAERD, Denmark I March 24, 2025 IThe United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) ...

PARIS, France I March 25, 2025 I The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to ...

NEW YORK, NY, USA I March 24, 2025 I On March 17, 2025, US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by ...